Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 26 for:    methylparaben

Vasopressin and the Social Brain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02394054
Recruitment Status : Completed
First Posted : March 20, 2015
Last Update Posted : August 10, 2017
Sponsor:
Information provided by (Responsible Party):
Matthew Lieberman, University of California, Los Angeles

Brief Summary:

It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, the investigators are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relationships. Recent research has begun to focus on vasopressin, a neuropeptide that is naturally produced in the hypothalamus, because administration of this neuropeptide has been associated with empathy, cooperation, memory of social stimuli (e.g., faces), and brain activity in neural regions associated with social and emotional processes. To date, several aspects of vasopressin's effects on social behavior have been unexplored. As such, the overarching goal of this project is to examine the effects of intranasal vasopressin on several tasks involving learning and social processes. In addition, the investigators will explore associated neural activity through functional magnetic resonance imaging (fMRI). Results from the study will inform our understanding of the neurobiology of socioemotional processes.

The investigators hypothesize that compared to placebo, vasopressin will improve deception detection, increase empathy and altruism, enhance responses to photo stimuli of primary caregivers, and improve learning when the subject has a prosocial goal of teaching another person. These effects will manifest in behavioral and neural activity. It is also hypothesized that main effects will not be found for vasopressin, but rather, analyses of relevant moderators will elucidate these findings.


Condition or disease Intervention/treatment Phase
Social Psychology Drug: Intranasal vasopressin Drug: Intranasal placebo Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Vasopressin's Effect on Behavior and Neural Activity During Social Cognition Tasks
Study Start Date : January 2015
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Vasopressin

Arm Intervention/treatment
Experimental: Intranasal vasopressin
Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
Drug: Intranasal vasopressin
Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).

Placebo Comparator: Intranasal placebo
2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
Drug: Intranasal placebo
Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.




Primary Outcome Measures :
  1. Changes in neural brain activity, as observed by fMRI, when observing others during social inclusion vs. exclusion [ Time Frame: Between 40-115 minutes post administration ]
    Whole brain and region of interest (ROI) regression analysis will be used to compare the neural activity of participants in the vasopressin/placebo groups. A design matrix will be created for each participant, modeling activity that is greater during the exclusion portion of the cyberball task (Williams et al., 2012) versus the inclusion portion. A first-level analysis will compare [(friend exclusion>friend inclusion)>(stranger exclusion>stranger inclusion)] for each participant. A second-level group analysis will compare these first-level contrasts between the vasopressin and placebo groups.


Secondary Outcome Measures :
  1. Ratings of empathic concern after witnessing social exclusion in a friend or a stranger [ Time Frame: Between 40-115 minutes post administration ]
    Ratings of empathic concern will be calculated for each participant by deriving a composite from self-report ratings of sympathy and compassion. Using a mixed 2 (friend, stranger) x 2 (vasopressin, placebo) factorial design, comparisons of these ratings will then be made for those in the vasopressin vs. placebo groups. Main effects of drug condition (vasopressin, placebo) as well as the interaction between drug condition and target (friend, stranger) will be analyzed at a significance level of p<.05.

  2. Altruism and punishment as measured by number of points given to excluders and those excluded [ Time Frame: Between 40-115 minutes post administration ]
    Ratings of altruism and punishment will be calculated by examining how many point (1-10) participants decide to allocate towards the friend-excluder, stranger-excluder, excluded friend, and excluded stranger after watching each social exclusion game. Using a mixed 2 (friend, stranger) x 2 (vasopressin, placebo) factorial design, comparisons of these ratings will then be made for those in the vasopressin vs. placebo groups. Main effects of drug condition (vasopressin, placebo) and target (friend, stranger), as well as an interaction between drug condition and target will be analyzed at a significance level of p<.05.

  3. Changes in neural brain activity, as observed by fMRI, while attempting to detect deception [ Time Frame: Between 40-115 minutes post administration ]
    Whole brain and region of interest (ROI) regression analysis will be used to compare the neural activity of participants in the vasopressin/placebo groups. A design matrix will be created for each participant, modeling activity that is greater during the deception detection task versus a control task. A first-level analysis will compare deception-detection>control for each participant. A second-level group analysis will compare this first-level contrast between the vasopressin and placebo groups.

  4. Accuracy of deception detection as measured by self-report [ Time Frame: Between 40-115 minutes post administration ]
    The investigators will compare the percentage of correct deception detection trials for participants in the vasopressin group to those in the placebo group by running a two-tailed t-test with a statistical cutoff of p<.05 to determine significance.

  5. Changes in neural brain activity, as observed by fMRI, when viewing images of primary caregivers versus strangers [ Time Frame: Between 40-115 minutes post administration ]
    Whole brain and region of interest (ROI) regression analysis will be used to compare the neural activity of participants in the vasopressin/placebo groups. A design matrix will be created for each participant, modeling activity that is greater while viewing photo stimuli of ones primary caregivers versus viewing photo stimuli of matched strangers. A first-level analysis will compare primary-caregiver-viewing>stranger-viewing for each participant. A second-level group analysis will compare this first-level contrast between the vasopressin and placebo groups.

  6. Changes in brain neural activity, observed by fMRI, in response to a reading comprehension task [ Time Frame: Between 40-90 minutes post administration ]
    Whole brain and region of interest (ROI) regression analysis will be used to compare the neural activity of participants in the tutor/memorizer and vasopressin/placebo groups. A design matrix will be created for each participant, modeling activity that is greater during reading comprehension compared with the grammar control passage. First level analyses will compare the response during the reading comprehension passages relative to the grammar control passages. Second level group analyses will compare the first level contrasts between the tutor vs. memorizer groups as well as the vasopressin vs. placebo groups. In regression analyses the investigators will enter each participant's comprehension test score in the tutor and then memorizer condition as a regressor in a whole-brain and ROI analysis to determine which brain regions were more active during the encoding of the reading comprehension passage compared to the grammar control passage.

  7. Performance on a memory test of reading comprehension as measured by percentage of questions answered correctly [ Time Frame: Between 40-90 minutes post administration ]
    Accuracy will be calculated for each participant by dividing the number of correct responses by the total number of questions. The investigators will then conduct a between-subjects 2x2 ANOVA on the accuracy scores for the four groups of interest (i.e., vasopressin-tutor, vasopressin-memorizer, placebo-tutor, placebo-memorizer). A significance level of p<.05 will be used to determine whether there are significant differences between the groups. The investigators will examine whether there is a main effect of either factor (vasopressin vs. placebo, tutor vs. memorize) as well as an interaction between the factors of interest.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-30 years of age
  • Healthy (see below)
  • Fluent in English
  • Right-handed

Exclusion Criteria:

  • Women who gave birth in the last six months, are currently pregnant, planning to become pregnant in the next 6 months, or currently breastfeeding women
  • Symptoms of runny nose due to allergies/cold or other reason
  • Current restricted fluid intake for any reason
  • Heart disease
  • Hypertension
  • History of myocardial infarction
  • History of cardiac arrhythmia
  • Kidney or liver disease
  • Vascular disease
  • Epilepsy
  • Migraine
  • Asthma
  • Nephritis
  • Diabetes and other endocrine diseases
  • Frequent or unexplained fainting
  • History of stroke
  • Aneurysm or brain hemorrhage
  • Active psychiatric diagnosis
  • Current psychopharmacologic treatment
  • Drug or alcohol abuse
  • Medical or neurological illness
  • Regular use of medication (e.g., vasoconstrictive medications)
  • Medication intake less than 2 weeks prior to study (5 weeks for fluoxetine) including daily non-steroidal anti-inflammatory drugs
  • Smoking more than 15 cigarettes a day
  • Consumption of any alcoholic beverages in the past 24 hours will be excluded
  • Elevated blood pressure (>135/90)
  • Low blood pressure (<90/55)
  • Body temperature >100.1 F
  • Left-handed
  • Claustrophobia
  • Presence of metal in their body

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02394054


Locations
Layout table for location information
United States, California
UCLA Department of Psychology
Los Angeles, California, United States, 90095-1563
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Matthew D Lieberman, PhD University of California, Los Angeles

Layout table for additonal information
Responsible Party: Matthew Lieberman, Matthew D. Lieberman, PhD, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT02394054     History of Changes
Other Study ID Numbers: 11-003565-3
First Posted: March 20, 2015    Key Record Dates
Last Update Posted: August 10, 2017
Last Verified: August 2017
Keywords provided by Matthew Lieberman, University of California, Los Angeles:
vasopressin
intranasal administration
healthy sample
Additional relevant MeSH terms:
Layout table for MeSH terms
Vasopressins
Arginine Vasopressin
Hemostatics
Coagulants
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs